Abstract
Does benefits of rivaroxaban as add-on to aspirin apply to diabetes-related cardiovascular disease? Insights from the COMPASS and VOYAGER PAD trials
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have